Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis

J Am Acad Dermatol. 1985 Jan;12(1 Pt 1):52-5. doi: 10.1016/s0190-9622(85)70008-4.

Abstract

Twenty five patients with severe and extensive psoriasis were treated with trimethylpsoralen (trioxsalen) bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (Ro 10-9359). Etretinate was started (1 mg/kg/day) 2 weeks prior to starting the bath PUVA treatment daily. Psoriasis cleared with fifteen treatments in 96% of patients with a mean total UVA dose of 3.9 joules/cm2. The control group of nine patients received only bath PUVA without retinoid, and eight of them cleared with nineteen treatments and with a mean UVA dose of 7.2 joules/cm2. In addition, three psoriatic patients previously resistant to bath PUVA treatment were given etretinate (1 mg/kg/day), and they cleared in 4 to 8 weeks after starting etretinate with a UVA dose of 37-144 joules/cm2. In the maintenance therapy after the combination therapy of twenty-four patients, the results of treatment were good or excellent in fourteen of fifteen patients (93%) getting only bath PUVA one to two times a week and in four of nine patients (44%) getting etretinate (25-50 mg daily) in a mean follow-up time of 10 weeks. These results show the benefits of the combination of trimethylpsoralen bath PUVA with an oral retinoid, etretinate, in the treatment of severe and extensive psoriasis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Baths*
  • Drug Therapy, Combination
  • Etretinate / administration & dosage
  • Etretinate / therapeutic use*
  • Follow-Up Studies
  • Furocoumarins / therapeutic use*
  • Humans
  • Middle Aged
  • PUVA Therapy* / adverse effects
  • Photochemotherapy* / adverse effects
  • Psoriasis / drug therapy*
  • Trioxsalen / therapeutic use*

Substances

  • Furocoumarins
  • Etretinate
  • Trioxsalen